ArticleMedicine2026
Potentially inappropriate medication use in older adult patients living with cancer using the Beers, STOPP, GO-PIM and Chinese criteria: A retrospective cross-sectional study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Due to the complexity of medication use in older adult patients living with cancer, the risk of potentially inappropriate medications (PIMs) was significantly increased, yet evaluation criteria vary. Therefore, this study aimed to detect the PIMs use by the 2023 American Geriatrics Society (AGS) Beers criteria, the 2023 Screening Tool of Older Persons' Prescriptions (STOPP) criteria, the geriatric oncology potentially inappropriate medication (GO-PIM) scale, and the 2024 Chinese criteria in older adult patients living with cancer and compare the prevalence of PIMs and the accordance between the 4 PIM criteria; and further to explore related risk factors for PIMs according to the 4 criteria. This retrospective study included 484 older adult patients living with cancer. PIMs were analyzed based on the 4 criteria. The consistency of the evaluation results was compared between the 4 criteria, and influencing factors for PIMs were analyzed using multivariate logistic regression. The incidence of PIMs in older adult patients living with cancer was high in our study, with certain differences in consistency among the 4 criteria. The 2024 Chinese criteria were the most sensitive for identifying PIMs, and polypharmacy was the main influencing factor for the occurrence of PIMs in all criteria. It is necessary to strengthen medication therapy management for older adult patients living with cancer. The prevalence of at least one PIM identified by the 4 criteria ranged from 42.15% to 71.07%. The drugs with the highest incidence were metoclopramide, medroxyprogesterone, and cimetidine. The kappa statistics for the 2023 AGS/Beers criteria with the 2024 Chinese criteria, the GO-PIM scale and 2024 Chinese criteria indicated a good concordance (κ = 0.788 and 0810). The consistency between the 2023 AGS/Beers criteria and the 2023 STOPP criteria, the GO-PIM scale were moderate (κ = 0.459 and 0732). The consistency between the 2023 STOPP criteria and the 2024 Chinese criteria was moderate (κ = 0.448), but with the GO-PIM scale was poor (κ = 0.345). The results of multiple logistic regression analysis showed that polypharmacy was the main influencing factor for the occurrence of PIMs in all criteria (P<.001).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.